Kardigan, Inc.

Kardigan is a clinical-stage precision therapeutics company focused on developing medicines for cardiovascular diseases where no approved treatments currently exist. The company's mission is to develop multiple targeted cardiovascular treatments in parallel to bring patients closer to cures. Kardigan leverages deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development. Kardigan is advancing three late-stage clinical programs. These include Danicamtiv, an investigational oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM) caused by pathogenic variants in MYH7 and TTN. Another program is Ataciguat, an investigational oral, once-daily soluble guanylate cyclase (sGC) activator aimed at slowing the progression of calcific aortic valve stenosis (CAVS). The third program is Tonlamarsen, an investigational liver-directed antisense oligonucleotide (ASO) for the management of blood pressure in acute severe hypertension (ASH) post-hospitalization. The company also operates Prolaio, a proprietary data and analytics platform that utilizes wearable sensors and AI-driven analytics to support clinical trials and digital clinical endpoints. Kardigan was founded in 2023 and is headquartered in South San Francisco, California, and Princeton, New Jersey. Sources: [1] https://stockanalysis.com/stocks/kard/company/ [2] https://www.renaissancecapital.com/Profile/KARD/Kardigan/IPO [3] https://pitchbook.com/profiles/company/731954-98 [4] https://www.kardigan.bio/about-us/ [5] https://www.ebc.com/forex/kardigan-ipo-8-things-to-know-before-kards-1-4b-nasdaq-debut [6] https://www.ipox.com/ipo-calendar/kardigan [7] https://www.biospace.com/press-releases/kardigan-launches-with-industry-leading-team-to-modernize-cardiovascular-drug-development-with-late-stage-portfolio-of-personalized-medicines